Cancer vaccine trial for colorectal cancer halted after just one patient
NCT ID NCT05350501
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of a therapeutic vaccine (EO2040) and an immunotherapy drug (nivolumab) in colorectal cancer patients who had minimal residual disease detected by a blood test after completing standard treatment. The goal was to clear remaining cancer cells and prevent recurrence. However, the study was terminated early after enrolling only one participant, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EO2040 (a therapeutic peptide vaccine) combined with nivolumab (an immunotherapy drug)
What this could lead to
If successful, this approach could help eliminate remaining cancer cells in colorectal cancer patients after standard treatment, potentially reducing the risk of recurrence.
What could go wrong
The trial was terminated early with only 1 participant, so no meaningful conclusions can be drawn. The combination may cause immune-related side effects, and its effectiveness is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson
Houston, Texas, 77030, United States